Antigen binding proteins that bind PD-L1
AssigneeSorrento Therapeutics, Inc.
InventorHeyue Zhou
Life of this patent
Estimating the term…
Abstract
There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
Claims17
A fully human antibody of an IgG class that binds to a PD-L1 epitope, wherein the antibody comprises a heavy chain variable domain comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain as set forth in the amino acid sequences of SEQ ID NO:
- 5, SEQ ID NO:
- 6, and SEQ ID NO:
- 7, respectively, and comprises a light chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2 or SEQ ID NO. 3.
An anti-PD-L1 Fab fully human antibody fragment having a variable domain from a heavy chain and a variable domain from a light chain, wherein the heavy chain variable domain comprises a CDR1 domain, a CDR2 domain, and a CDR3 domain as set forth in the amino acid sequences of SEQ ID NO:
- 5, SEQ ID NO:
- 6, and SEQ ID NO:
- 7, respectively, and wherein the light chain variable domain comprises an amino acid sequence as set forth in SEQ ID NO. 2 or SEQ ID NO. 3.
An anti-PD-L1 single chain human antibody having a heavy chain variable domain and a light chain variable domain connected via a peptide linker, wherein the heavy chain variable domain comprises a CDR1 domain, a CDR2 domain, and a CDR3 domain as set forth in the amino acid sequences of SEQ ID NO:
- 5, SEQ ID NO:
- 6, and SEQ ID NO:
- 7, respectively, and wherein the light chain variable domain comprises an amino acid sequence as set forth in either SEQ ID NO. 2 or SEQ ID NO. 3.
Dependencies are inferred from the claim text.